The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
Official Title: A Multi-center, Randomized, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AK105 Plus Anlotinib and CapeOx, Anlotinib in Combination With CapeOx Versus Bevacizumab in Combination With CapeOx in the Fisrt-line Treatment of Unresectable Metastatic Colorectal Cancer
Study ID: NCT05068206
Brief Summary: A clinical study to compare the efficacy and safety of AK105 plus anlotinib and Capecitabine/Oxaliplatin (CapeOx) , anlotinib plus CapeOx, bevacizumab plus CapeOx. A total of 120 cases will be enrolled to the group.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
First Hospital of Lanzhou University, Lanzhou, Gansu, China
Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Sun Yixian Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Scinece and Technology, Luoyang, Henan, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
Subei People's Hospital, Yangzhou, Jiangsu, China
Jilin Cancer Hospital, Changchun, Jilin, China
Shandong Cancer Hospital, Jinan, Shandong, China
Shanghai East Hospital, Shanghai, Shanghai, China